Abstract
Mucormycosis has emerged as an important opportunistic infection, especially in severely immunosuppressed hosts. The evolving epidemiology, immunopathogenesis, molecular virulence studies, early diagnosis, and pitfalls in designing clinical studies of mucormycosis are discussed in this article.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antifungal Agents / pharmacology
-
Aspergillus / genetics
-
Aspergillus / immunology
-
Aspergillus / pathogenicity*
-
Biomedical Research
-
Early Diagnosis
-
Genome, Fungal
-
Humans
-
Immunocompromised Host
-
Mucormycosis / diagnosis
-
Mucormycosis / drug therapy
-
Mucormycosis / epidemiology*
-
Mucormycosis / pathology
-
Pyrimidines / pharmacology
-
Rhizopus / genetics
-
Rhizopus / immunology
-
Rhizopus / pathogenicity*
-
Risk Factors
-
Triazoles / pharmacology
-
Voriconazole
Substances
-
Antifungal Agents
-
Pyrimidines
-
Triazoles
-
Voriconazole